At the Saturday, Oct. 22 session, ‘Basic Science: Correlates of protection, immune response and the host-microbe interaction,’ of the IDWeek 2022 infectious disease conference, moderator Luiz Bermudez, professor at Oregon State University, introduced the latest advances to prevent infections with Treponema pallidum during neurosyphilis (NS), Staphylococcus aureus and osteomyelitis, and Mycobacterium tuberculosis during influenza. Read More
Investigators working at University of Texas Health Science Center, Houston, have discovered that the ubiquitin ligase UBR2 is up-regulated and sufficient for targeting the myosin heavy chain protein for the degradation characteristic of cancer cachexia. UBR2 knockout or pharmacological inhibition could prevent cachexia in mice. Confirmatory observations were noted in cancer cachexia patient-derived tissues. Read More
Rational drug design based on EPI-X4, endogenous antagonist of C-X-C motif chemokine receptor (CXCR4), led to the identification of optimized analogues named JMF-01 to JMF-07, which demonstrated increased antagonistic activity. Read More
VPO-227 is a small molecule with a novel mechanism of action, which blocks the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel. Read More
Xi'an Xintong Medicine Research Co. Ltd. has synthesized 1,3-benzodioxolane-containing compounds acting as dual Bruton tyrosine kinase (BTK) and tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of rheumatoid arthritis and B-cell lymphoma. Read More
Researchers from Astellas Pharma Inc. presented preclinical data for the novel 5-HT5A receptor antagonist, ASP-5736, being developed for the treatment of fragile X syndrome (FXS). Read More
A recent Canwell Biotech Ltd. patent details the discovery of methionine aminopeptidase-2 (MetAP2) inhibitors reported to be useful for the treatment of cancer, diabetes, obesity, rheumatoid arthritis and psoriasis. Read More
Yiteng Pharmaceutical Industry Taizhou Co. Ltd. has described cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer. Read More
RNA binding fox-1 homologue 1 (RBFOX1) is a splicing factor that regulates alternative splicing and modulates the expression of several genes involved in brain development, and it is among the top identified loci related to psychiatric disorders.
Read More
Humanwell Healthcare (Group) Co. Ltd. has disclosed pyrimidopyrazine compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer. Read More
Medshine Discovery Inc. has patented selenium-containing compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of cancer. Read More
The British Columbia Cancer Agency recently discussed their research efforts toward the discovery of new radiotherapeutic agents for the treatment of prostate cancer. Read More
